SCHEMBL255378

SCHEMBL255378

Fc1cccc(N2CCCC2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
KMT2A Q03164 1/20 0.52
HSD17B10 Q99714 1/20 0.52
BPTF Q12830 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
NPC1 O15118 2/20 0.50
MAPT P10636 2/20 0.50
RAB9A P51151 2/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
ALOX5 P09917 1/20 0.49
AGXT P21549 1/20 0.49
C1S P09871 1/20 0.48
PRMT6 Q96LA8 1/20 0.47
FAAH O00519 2/20 0.47
MGLL Q99685 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30167608 1.00 ALDH1A1 (0.52) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL3159432 0.98 SMN1; SMN2 (0.50) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL30407553 0.96 BPTF (0.51) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL20699709 0.91 BPTF (0.54) ALDH1A1MEN1GAAKMT2ABPTF
SCHEMBL10373948 0.91 BPTF (0.54) ALDH1A1MEN1GAAKMT2ABPTF
SCHEMBL27955969 0.89 KDM4E (0.47) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL29709387 0.88 BPTF (0.46) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL456094 0.87 SMN1; SMN2 (0.49) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL1267656 0.83 BPTF (0.49) ALDH1A1MEN1GAAKMT2ABPTF
Hydrochloric Acid SCHEMBL12817391 0.82 HTR1A (0.59) ALDH1A1MAPTTP53HTTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388587-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN SHANGHAI INC (CN) 2025-12-25 US disclosed
US-20240400570-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2024-12-05 US disclosed
US-12065442-B2 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use CULLGEN (SHANGHAI), INC. (CN) 2024-08-20 US disclosed
US-11969472-B2 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use CULLGEN (SHANGHAI), INC. (CN) 2024-04-30 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
EP-4157888-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS Cullgen (Shanghai), Inc. (CN) 2023-04-05 EP disclosed
EP-4110772-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE Cullgen (Shanghai), Inc. (CN) 2023-01-04 EP disclosed
WO-2021239117-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI) , INC. (CN) 2021-12-02 WO disclosed
US-20210246147-A1 PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) Valo Health, LLC 2021-08-12 US disclosed
EP-2155669-A1 NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-02-24 EP disclosed
WO-2009090054-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-07-23 WO disclosed
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2009-06-25 US disclosed
WO-2008148799-A1 NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2008-12-11 WO disclosed
WO-2008148801-A2 DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2008-12-11 WO disclosed
EP-1707202-A1 Organic compounds Speedel Experimenta AG (CH) 2006-10-04 EP disclosed
WO-2005037803-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-04-28 WO disclosed
US-5140040-A Alpha-2-adrenergic receptor antagonist; glaucoma; congestive heart failure; hypotensive agents; headaches; metabolic disorders (diabetes, obesity) ABBOTT LABORATORIES (US) 1992-08-18 US disclosed
US-5128362-A Antidepressant, antiglaucoma ABBOTT LABORATORIES (US) 1992-07-07 US disclosed
US-5086074-A Selective adrenergic receptor antagonists ABBOTT LABORATORIES (US) 1992-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11969472-B2 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use MUSK, ERBB2, NTRK1 ALDH1A1 4113/4885KDM4E 3125/4885MEN1 3599/4885
US-20250388587-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE ERBB2, MUSK, ERBB3 ALDH1A1 4483/4885KDM4E 3350/4885MEN1 4799/4885
US-20240400570-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, ERBB2, NTRK1 ALDH1A1 4113/4885KDM4E 3125/4885MEN1 3599/4885
US-20210246147-A1 PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) NAMPT, NAPRT, NNMT ALDH1A1 265/4885KDM4E 2054/4885MEN1 2895/4885
US-12065442-B2 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use MUSK, NTRK1, ERBB2 ALDH1A1 3928/4885KDM4E 3368/4885MEN1 3553/4885
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof OPRL1, GRIN3B, GRIN3A ALDH1A1 1813/4885KDM4E 3994/4885MEN1 3590/4885
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 ALDH1A1 1273/4885KDM4E 2133/4885MEN1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.